<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1700">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139030</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-335</org_study_id>
    <nct_id>NCT05139030</nct_id>
  </id_info>
  <brief_title>Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered Via Adductor Canal Block for Postsurgical Analgesia in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare magnitude of postsurgical analgesic effect in&#xD;
      different groups following a single dose of study drug when administered via adductor canal&#xD;
      block in subjects undergoing primary unilateral total knee arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, active-controlled study in&#xD;
      approximately 160 subjects undergoing primary unilateral TKA under spinal anesthesia. The&#xD;
      study will have 2 cohorts, enrolling in parallel.&#xD;
&#xD;
      Cohort 1 -PK, PD, Efficacy, and Safety, Cohort 2 -Efficacy and Safety&#xD;
&#xD;
      An adaptive study design will be used in this study. An interim analysis to evaluate the&#xD;
      sample size assumptions and evaluate futility will occur when a total of approximately 80&#xD;
      subjects (40 subjects in each arm) combined from either Cohort 1 or Cohort 2 have enrolled&#xD;
      and provided complete assessment data for the primary efficacy outcome.&#xD;
&#xD;
      The time from study drug administration until the end of participation is POD 14 (±3 days).&#xD;
      Therefore, subjects may participate in the study for up to 62 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only study drug administrators (anesthesiologists) will be unblinded to perform the block procedures</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NRS scores through 96 hours post-surgery</measure>
    <time_frame>0 to 96 hours post-surgery</time_frame>
    <description>The area under the curve (AUC) of the NRS pain intensity scores from 0 to 96 hours post-surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postsurgical Opioid Consumption through 96 hours post-surgery</measure>
    <time_frame>0 to 96 hours post-surgery</time_frame>
    <description>Total postsurgical opioid consumption in oral morphine equivalents (OMED) from 0 to 96 hours post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid</measure>
    <time_frame>0 to 96 hours post-surgery</time_frame>
    <description>Time to first opioid consumption post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS scores</measure>
    <time_frame>0-24hours, 0-48hours, 0-72hours, 0-96hours</time_frame>
    <description>Worst and average NRS pain intensity scores at 24h, 48h, 72h and 96h from the end of surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Cohort 1: EXPAREL admix arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Bupivacaine HCl arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: EXPAREL admix arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Bupivacaine HCl arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine liposome injectable suspension</intervention_name>
    <description>Adductor canal block with EXPAREL</description>
    <arm_group_label>Cohort 1: EXPAREL admix arm</arm_group_label>
    <arm_group_label>Cohort 2: EXPAREL admix arm</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Adductor Canal Block with bupivacaine HCl</description>
    <arm_group_label>Cohort 1: Bupivacaine HCl arm</arm_group_label>
    <arm_group_label>Cohort 2: Bupivacaine HCl arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ages 18 or older at screening.&#xD;
&#xD;
          2. Indicated to undergo primary unilateral total knee arthroplasty under spinal&#xD;
             anesthesia.&#xD;
&#xD;
          3. Primary indication for TKA is degenerative osteoarthritis of the knee.&#xD;
&#xD;
          4. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.&#xD;
&#xD;
          5. Able to provide informed consent, adhere to the study schedule, and complete all study&#xD;
             assessments.&#xD;
&#xD;
          6. Body Mass Index (BMI) ≥18 and &lt;40 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study&#xD;
             medications for which an alternative is not named in the protocol (e.g., amide-type&#xD;
             local anesthetics, opioids, bupivacaine HCl, NSAIDs).&#xD;
&#xD;
          2. Planned concurrent surgical procedure (e.g., bilateral TKA).&#xD;
&#xD;
          3. Undergoing unicompartmental TKA or revision TKA.&#xD;
&#xD;
          4. Concurrent painful physical condition (e.g., arthritis, fibromyalgia, cancer) that may&#xD;
             require analgesic treatment with NSAIDs or opioids in the post dosing period for pain&#xD;
             that is not strictly related to the knee surgery and which, in the Investigator's&#xD;
             opinion, may confound the post dosing assessments.&#xD;
&#xD;
          5. Inadequate sensory function below the knee as assessed by the Investigator.&#xD;
&#xD;
          6. History of contralateral TKA within 1 year.&#xD;
&#xD;
          7. Previous open knee surgery on the knee being considered for TKA. Prior arthroscopy is&#xD;
             permitted.&#xD;
&#xD;
          8. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
&#xD;
          9. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study.&#xD;
&#xD;
         10. Previous participation in an EXPAREL study.&#xD;
&#xD;
         11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the&#xD;
             opinion of the Investigator, could interfere with study assessments or compliance.&#xD;
&#xD;
         12. Currently pregnant, nursing, or planning to become pregnant during the study.&#xD;
&#xD;
         13. Clinically significant medical disease that, in the opinion of the Investigator, would&#xD;
             make participation in a clinical study inappropriate. This includes diabetic&#xD;
             neuropathy, coagulation or bleeding disorders, severe peripheral vascular disease,&#xD;
             renal insufficiency, hepatic dysfunction, or other conditions that would constitute a&#xD;
             contraindication to participation in the study.&#xD;
&#xD;
         14. Currently on a neuromodulating agent (e.g., gabapentin, pregabalin [Lyrica],&#xD;
             duloxetine [Cymbalta], etc.)].&#xD;
&#xD;
         15. Current use of systemic glucocorticoids within 30 days of randomization in this study.&#xD;
&#xD;
         16. Use of dexmedetomidine HCl (Precedex®) or clonidine within 3 days of study drug&#xD;
             administration.&#xD;
&#xD;
         17. Any use of marijuana [including Tetrahydrocannabinol (THC) and Cannabidiol (CBD)]&#xD;
             within 30 days prior to randomization, or planned use during the course of the study.&#xD;
&#xD;
         18. Chronic opioid use (average ≥30 oral morphine equivalents/day) within 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
        Given the COVID-19 pandemic, if there is a concern about a subject's recent or potential&#xD;
        exposure to COVID-19, or if the subject is not medically fit/cleared for surgery due to&#xD;
        suspected COVID-19 illness/symptoms, the subject must be excluded per Exclusion criterion&#xD;
        #13.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Nevins</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Shaffer</last_name>
    <phone>973-451-4071</phone>
    <email>sarah.shaffer@pacira.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Barros</last_name>
    <phone>973-451-4041</phone>
    <email>alice.barros@pacira.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EXPAREL</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>analgesic</keyword>
  <keyword>Adductor Canal Block</keyword>
  <keyword>TKA</keyword>
  <keyword>knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

